Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.